QTRX - Quanterix Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.95
-0.83 (-3.81%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close21.78
Open21.65
Bid16.50 x 1200
Ask20.94 x 900
Day's Range20.82 - 22.08
52 Week Range16.00 - 36.15
Volume133,575
Avg. Volume220,171
Market Cap582.831M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.64
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.00
Trade prices are not sourced from all markets
  • 3 Medical Product Stocks Likely to Beat This Earnings Season
    Zacks

    3 Medical Product Stocks Likely to Beat This Earnings Season

    Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

  • Business Wire

    Quanterix Announces Recipients of Annual Accelerator Grant Program

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Shelli Kesler, Ph.D., and Ashley Henneghan, Ph.D., MSN, from the School of Nursing at the University of Texas at Austin, as the winners of its annual Accelerator Grant Program for their research proposal, “Neurodegenerative and Inflammatory Predictors of Cancer Related Cognitive Impairment in Breast Cancer Patients.” As recipients of the grant, Quanterix will award $50,000 toward the cost of their research in the company’s Accelerator Lab using Quanterix’ ultrasensitive Simoa technology.

  • Need To Know: Quanterix Corporation (NASDAQ:QTRX) Insiders Have Been Selling Shares
    Simply Wall St.

    Need To Know: Quanterix Corporation (NASDAQ:QTRX) Insiders Have Been Selling Shares

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • Business Wire

    Powering Precision Health Announces 2019 Summit

    Powering Precision Health (PPH), the internationally-acclaimed Summit focused on precision health and the latest in biomarker research, today announced much-anticipated details for its 2019 Summit, which will take place in Barcelona on November 19. Led by precision medicine pioneer, Kevin Hrusovsky, PPH is a non-profit organization with the mission of transforming healthcare from today’s paradigm of scrambling to treat diseases late in their progression to one focused on precision and personalized treatments early in the disease cascade long before symptoms present using cutting-edge biomarker “early and non-invasive detection” technology.

  • Business Wire

    Quanterix Serum Nf-L Assay Powers Key Trial and Study Results Presented at ECTRIMS 2019

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Simoa technology and Nf-L assays were used in many of the groundbreaking research and treatment developments presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Prior to the beginning of the conference, Quanterix announced that presentations leveraging Simoa increased by 40 percent from the 2018 ECTRIMS event, to a total of 49 references. The widespread adoption of Quanterix’ technology demonstrates the value it brings to advancing disease diagnosis and monitoring for Multiple Sclerosis.

  • Business Wire

    Quanterix Simoa Technology Powers Multiple Sclerosis Research with More Than 50 Presentations at ECTRIMS 2019

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology has been referenced in more than 50 new research studies to be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), from Sept. 11-13, 2019 in Stockholm, Sweden. The number of presentations leveraging Simoa increased by over 40 percent since last year’s event, demonstrating widespread adoption of Quanterix’ technology by leading researchers dedicated to advancing disease diagnosis and monitoring for Multiple Sclerosis.

  • Quanterix Corporation (QTRX) Q2 2019 Earnings Call Transcript
    Motley Fool

    Quanterix Corporation (QTRX) Q2 2019 Earnings Call Transcript

    QTRX earnings call for the period ending June 30, 2019.

  • Business Wire

    Quanterix Announces Kevin Hrusovsky, Chairman and Chief Executive Officer, and Founder of Powering Precision Health, as EY Entrepreneur Of The Year® 2019 Award Winner in New England

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chairman and CEO of Quanterix, and Founder of Powering Precision Health (PPH), has been recognized with the Entrepreneur Of The Year® 2019 Award in the New England region by EY. The award acknowledges Hrusovsky’s achievements in healthcare technology innovation, Quanterix’ outstanding financial performance, and his personal commitment to improving precision health. “We are honored to be recognized by EY,” said Hrusovsky.

  • Business Wire

    Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock. Uman is widely recognized to possess the leading antibodies available today to measure neurofilament light (Nf-L) and has become the provider of choice for biopharmaceutical and diagnostic applications.

  • Did Quanterix's (NASDAQ:QTRX) Share Price Deserve to Gain 66%?
    Simply Wall St.

    Did Quanterix's (NASDAQ:QTRX) Share Price Deserve to Gain 66%?

    If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

  • Business Wire

    Quanterix Raises $49.7 Million and Announces Introduction of Latest Model Simoa HD-X Analyzer at BIO 2019 International Convention

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced that it issued approximately 2.2 million shares of common stock last week, raising $49.7 million in gross proceeds. Additionally, Quanterix will unveil its Simoa HD-X Analyzer™, at the BIO International Convention, in Philadelphia, during a presentation by its Chairman and CEO, Kevin Hrusovsky, taking place June 5 at 10:45 a.m., EDT, in Theater 3. Quanterix is re-engineering ultra-sensitivity with the launch of the HD-X, its latest fully automated Simoa bead-based immunoassay instrument model.

  • Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its Disruptive Simoa Platforms
    Business Wire

    Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its Disruptive Simoa Platforms

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the relocation of its headquarters to a brand new, state-of-the-art facility in Billerica, Mass. Brought on by Quanterix’ rapid growth, the move will allow the Company to unite its CLIA-certified laboratory with its expanding workforce to accelerate entry into pharmaceutical drug services and further increase its impact on the transformation of precision healthcare. “We experienced considerable success in our former facilities, launching several new biomarker technologies that are beginning to disrupt drug development and drug approval methodologies, acquiring Aushon to accelerate our entry into Biopharma services and leading a successful public offering in December 2017,” said Kevin Hrusovsky, Chairman and CEO, Quanterix.

  • Business Wire

    Quanterix Announces $50,000 in Grants to Support Promising Oncology Research

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a call for proposals for a new Accelerator Grant Program. Designed to help facilitate breakthroughs in science and medicine, this year’s Accelerator Grant Program will award up to $50,000 toward the cost of research in Quanterix’ Accelerator Lab to help advance the most exciting biomarker research using Quanterix’ ultrasensitive Simoa technology.

  • Here’s What Hedge Funds Think About Quanterix Corporation (QTRX)
    Insider Monkey

    Here’s What Hedge Funds Think About Quanterix Corporation (QTRX)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • Quanterix Corporation (QTRX) Q1 2019 Earnings Call Transcript
    Motley Fool

    Quanterix Corporation (QTRX) Q1 2019 Earnings Call Transcript

    QTRX earnings call for the period ending March 31, 2019.